Impel Pharmaceuticals Inc Net Income per Employee (IMPL), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Impel Pharmaceuticals Inc   (NASDAQ: IMPL)
 

Impel Pharmaceuticals Inc Net Income per Employee

IMPL's Quarterly Results, Trends, Rankings, Statistics
Impel Pharmaceuticals Inc recorded a cumulative net loss of $-74 million during 12 month ending in the third quarter 2023.
The Healthcare sector has seen employees of 254 other companies achieving higher income per employee. While Impel Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 3966.


What is Income per Employee Ratio?






IMPL Net Income per Employee (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -834,596 -1,028,787 -1,229,315 -1,194,517 -1,213,629
IMPL's Total Ranking # 3966 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


IMPL Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 255
Healthcare Sector # 655
Overall Market # 3966

Net Income per Employee Statistics
High Average Low
$ -126,865 $ -963,238 $ -1,229,315
(Mar 31 2021)   (Mar 31 2023)







Companies with similar Income per Employee for 12 month ending Sep 30 2023, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2023Number of Employees Sep 30 2023


Date modified: 2026-08-29T17:43:47+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.